Kadimastem

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

Kadimastem Raises $5 million In Private Placement

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes